Recurrent tuberculosis in Houston, Texas: A population-based study

International Journal of Tuberculosis and Lung Disease

Volumn 8, Issue 3, 2004, Pages 333-340

  El Sahly, H M ^a   Wright, J A ^a   Soini, H ^a   Bui, T T ^a   Williams Bouyer, N ^a   Escalante, P ^b   Musser, J M ^c   Graviss, Edward A ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Genotyping; Molecular epidemiology; Reinfection

Indexed keywords

ISONIAZID; RIFAMPICIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; CONSULTATION; DATA BASE; DEMOGRAPHY; DISEASE ASSOCIATION; GENERAL PRACTITIONER; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INFECTION RATE; LUNG DISEASE; MAJOR CLINICAL STUDY; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; MYCOBACTERIUM TUBERCULOSIS; POPULATION RESEARCH; PRIORITY JOURNAL; RECURRENT DISEASE; REINFECTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RETROSPECTIVE STUDY; TUBERCULOSIS; UNEMPLOYMENT; UNITED STATES; VULNERABLE POPULATION;

ADULT; CARRIER STATE; CASE-CONTROL STUDIES; CITIES; HUMANS; MYCOBACTERIUM TUBERCULOSIS; POPULATION SURVEILLANCE; RECURRENCE; RISK FACTORS; SOCIOECONOMIC FACTORS; TEXAS; TUBERCULOSIS; URBAN HEALTH;

EID: 2442610959     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Centers for Disease Control and Prevention. Division of Tuberculosis Elimination. Atlanta, GA: CDC, 2000. Available at: http://www.cdc.gov/nchstp/tb/surv/surv2000.
2. Garcia-Garcia M, Ponce-de León A, Jimenez-Corona M E, et al. Clinical consequences and transmissibility of drug-resistant tuberculosis in Southern Mexico. Arch Intern Med 2000; 160: 630-636.
3. Granich R M, Balandrano S, Santaella A J, et al. Survey of drug resistance of Mycobacterium tuberculosis in 3 Mexican states, 1997. Arch Intern Med 2000; 160: 639-644.
4. Fujiwara, P I, Cook S V, Rutherford C M, et al. A continuing survey of drug-resistant tuberculosis, New York City, April 1994. Arch Intern Med 1997; 157: 531-536.
5. Cohn D L, Bustreo F, Raviglione M C. Drug-resistant tuberculosis: review of the worldwide situation and the WHO/IUATLD global surveillance project. Clin Infect Dis 1997; 24 (Suppl): S121-S130.
6. Espinal M A, Laserson K, Camacho M, et al. Determinants of drug-resistant tuberculosis: analysis of 11 countries. Int J Tuberc Lung Dis 2001; 5: 887-893.
7. Centers for Disease Control and Prevention. Patients with recurrent tuberculosis. Morb Mortal Wkly Rep 1982; 30: 645-647.
8. Weis S E, Slocum P C, Blais F X, et al. The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis. N Engl J Med 1994; 330: 1179-1184.
9. Kopanoff D E, Snider D E, Johnson M. Recurrent tuberculosis: why do patients develop disease again? A United States Public Health Service Cooperative Survey. Am J Public Health 1988; 78: 30-33.
10. Benator D, Bhattacharya M, Bozeman L, et al. Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomized clinical trial. Lancet 2002; 360: 528-534.
11. Hawken M, Nunn P, Gathua S, et al. Increased recurrence of tuberculosis in HIV-1-infected patients in Kenya. Lancet 1993; 342: 332-337.
12. Mallory K F, Churchyard G J, Kleinschmidt I, De Cock K M, Corbett E L. The impact of HIV infection on recurrence of tuberculosis in South African gold miners. Int J Tuberc Lung Dis 2000; 4: 455-462.
13. Driver C R, Munsiff S S, Li J, Kundamal N, Osahan S S. Relapse in persons treated for drug-susceptible tuberculosis in a population with high coinfection with human immunodeficiency virus in New York City. Clin Infect Dis 2001; 33: 1762-1769.
14. Fitzgerald D W, Desvarieux M, Severe P, Joseph P, Johnson W D, Pape J W. Effect of post-treatment isoniazid on prevention of recurrent tuberculosis in HIV-1-infected individuals: a randomized trial. J Acquir Immune Defic Syndr 2000; 356: 1470-1474.
15. Sterling T R, Alwood K, Gachuhi R, et al. Relapse rates after short-course (6-month) treatment of tuberculosis in HIV-infected and uninfected persons. AIDS 1999; 13: 1899-1904.
16. Connolly C, Reid A, Davies G, Sturm W, McAdam K P, Wilkinson D. Relapse and mortality among HIV-infected and uninfected patients with tuberculosis successfully treated with twice weekly directly observed therapy in rural South Africa. AIDS 1999; 13: 1543-1547.
17. Stead W W, Bates J H, de Boer A S, et al. Recurrent tuberculosis due to exogenous re-infection. N Engl J Med 2000; 342: 1050-1051.
18. Bandera A, Gori A, Catozzi L, et al. Molecular epidemiology study of exogenous re-infection in an area with a low incidence of tuberculosis. J Clin Microbiol 2001; 39: 2213-2218.
19. van Rie A, Warren R, Richardson M, et al. Exogenous reinfection as a cause of recurrent tuberculosis after curative treatment. N Engl J Med 1999; 341: 1174-1179.
20. Caminero J A, Rena M J, Campos Herrero M I, et al. Exogenous re-infection with tuberculosis on a European island with a moderate incidence of disease. Am J Respir Crit Care Med 2001; 163: 717-720.
21. Bass J B Jr, Farer L S, Hopewell P C, et al. Treatment of tuberculosis and tuberculosis infection in adults and children. American Thoracic Society and the Centers for Disease Control and Prevention. Am J Respir Crit Care Med 1994; 149: 1359-1374.
22. Sreevastan S, Pan X, Stockbauer K E, et al. Restricted structural gene polymorphism in the M. tuberculosis complex indicates evolutionarily recent global dissemination. Proc Natl Acad Sci USA 1997; 94: 9869-9874.
23. van Embden J D A, Cave M D, Crawford J T, et al. Strain identification of M. tuberculosis by DNA fingerprinting: recommendations for a standard methodology. J Clin Microbiol 1993; 31: 406-409.
24. Kamerbeek J, Schouls L, Kolk A, et al. Simultaneous detection and strain differentiation of Mycobacterium tuberculosis for diagnosis and epidemiology. J Clin Microbiol 1997; 35: 907-914.
25. World Health Organization. WHO tuberculosis programme: framework for effective tuberculosis control. Geneva, Switzerland: WHO, 1997.
26. Daley C L, Small P M, Schecter G F, et al. An outbreak of tuberculosis with accelerated progression among persons infected with human immunodeficiency virus infection: an analysis using restriction-fragment-length-polymorphisms. N Engl J Med 1992; 326: 231-235.
27. Selwyn P A, Hartel D, Lewis V A, et al. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med 1989; 320: 545-550.
28. Zhang M, Gong J, Iyer D V, Jones B E, Modlin R L, Barnes P F. T cell cytokine responses in persons with tuberculosis and human immunodeficiency virus infection. J Clin Invest 1994; 94: 2435-2442.
29. Brindle R, Nunn P P, Githui W, Allen B W, Gathua S, Waiyaki P. Quantitative bacillary response to treatment in HIV-associated pulmonary tuberculosis. Am Rev Respir Dis 1993; 147: 958-961.
30. Chaisson R E, Clermont H C, Holt E A, et al. Six-month supervised intermittent tuberculosis therapy in Haitian patients with and without HIV infection. Am J Respir Crit Care Med 1996; 154: 1034-1038.
31. Kassim S, Sassan-Morokro M, Ackah A, et al. Two-year follow-up of persons with HIV-1-and HIV-2-associated pulmonary tuberculosis treated with short-course chemotherapy in West Africa. AIDS 1995; 9: 1185-1191.
32. Perriëns J H, St. Louis M E, Mukadi Y B, et al. Pulmonary tuberculosis in HIV-infected patients in Zaire. A controlled trial of treatment for 6 or 12 months. N Engl J Med 1995; 332: 779-784.
33. Teeter L D, Bui T T, Musser J M, Graviss E A. The effect of highly active antiretroviral therapy (HAART) on tuberculosis incidence in Houston, Texas. [abstract 244]. Chicago, IL: Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, 2001.
34. Espinal M A, Laszlo A, Simonsen L, et al. Global trends in resistance to antituberculosis drugs. N Engl J Med 2001; 344: 1294-1303.
35. Vynnycky E, Fine P E. The natural history of tuberculosis: the implications of age-dependent risks of disease and the role of re-infection. Epidemiol Infect 1997; 119: 183-201.
36. Stone M L. The utility of geographical information systems (GIS) and spatial analysis in tuberculosis surveillance in Harris County, Texas, 1995-1998. Master's thesis. Houston, TX; University of Texas, Houston School of Public Health, 2001.
37. Braden C R, Morlock G P, Woodley C L, et al. Simultaneous infection with multiple strains of Mycobacterium tuberculosis. Clin Infect Dis 2001; 33: 42-47.
38. Bates J H, Stead W W, Rado T A. Phage type of tubercle bacilli isolated from patients with two or more sites of organ involvement. Am Rev Respir Dis 1976; 114: 353-358.
39. Mankiewicz E, Liivak M. Phage types of Mycobacterium tuberculosis in pulmonary tuberculosis: report of 9 cases. Am Rev Respir Dis 1975; 112: 497-503.